Natalia A. Shnayder

Prof. Dr. Natalia A. Shnayder

V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology, Saint Petersburg, Sankt-Peterburg, Russia
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
NPNikolai N. Potekaev
Nikolai N. Potekaev
OBOlga Borzykh
Olga Borzykh
GMGerman Medvedev
German Medvedev
DPDenis V. Pushkin
Denis V. Pushkin
MPMarina Petrova
Marina Petrova
Natalia A. ShnayderNatalia A. Shnayder
Natalia A. Shnayder
Impaired wound healing is one of the unsolved problems of modern medicine, affecting patients’ quality of life and causing serious economic losses. Impaired wound healing can manifest itself in the form of chronic skin wounds or hypertrophic scars. Research on the biology and physiology of skin wound healing disorders is actively continuing, but, unfortunately, a single understanding has not been developed. The attention of clinicians to the biological and physiological aspects of wound healing in the skin is necessary for the search for new and effective methods of prevention and treatment of its consequences. In addition, it is important to update knowledge about genetic and non-genetic factors predisposing to impaired wound healing in order to identify risk levels and develop personalized strategies for managing such patients. Wound healing is a very complex process involving several overlapping stages and involving many factors. This thematic review focuses on the extracellular matrix of the skin, in particular its role in wound healing. The authors analyzed the results of fundamental research in recent years, finding promising potential for their transition into real clinical practice.

16 January 2023 in Metabolites
Verified
Journal Article
Open access
PDF file
Natalia A. ShnayderNatalia A. Shnayder
Natalia A. Shnayder
Violetta V GrechkinaVioletta V Grechkina
Violetta V Grechkina
Aiperi Kylychbekovna KhasanovaAiperi Kylychbekovna Khasanova
Aiperi Kylychbekovna Khasanova
EBElena N. Bochanova
Elena N. Bochanova
EDEvgenia A. Dontceva
Evgenia A. Dontceva
RNRegina F. Nasyrova
Regina F. Nasyrova
Valproic acid (VPA) and its salts are psychotropic drugs that are widely used in neurological diseases (epilepsy, neuropathic pain, migraine, etc.) and psychiatric disorders (schizophrenia, bipolar affective disorder, addiction diseases, etc.). In addition, the indications for the appointment of valproate have been expanding in recent years in connection with the study of new mechanisms of action of therapeutic and toxic metabolites of VPA in the human body. Thus, VPA is considered a component of disease-modifying therapy for multiple tumors, neurodegenerative diseases (Huntington’s disease, Parkinson’s disease, Duchenne progressive dystrophy, etc.), and human immunodeficiency syndrome. The metabolism of VPA is complex and continues to be studied. Known pathways of VPA metabolism include: β-oxidation in the tricarboxylic acid cycle (acetylation); oxidation with the participation of cytochrome P-450 isoenzymes (P-oxidation); and glucuronidation. The complex metabolism of VPA explains the diversity of its active and inactive metabolites, which have therapeutic, neutral, or toxic effects. It is known that some active metabolites of VPA may have a stronger clinical effect than VPA itself. These reasons explain the relevance of this narrative review, which summarizes the results of studies of blood (serum, plasma) and urinary metabolites of VPA from the standpoint of the pharmacogenomics and pharmacometabolomics. In addition, a new personalized approach to assessing the cumulative risk of developing VPA-induced adverse reactions is presented and ways for their correction are proposed depending on the patient’s pharmacogenetic profile and the level of therapeutic and toxic VPA metabolites in the human body fluids (blood, urine).

Verified
Journal Article
Open access
PDF file
Natalia A. ShnayderNatalia A. Shnayder
Natalia A. Shnayder
AAAzamat Ashkhotov
Azamat Ashkhotov
VTVera Trefilova
Vera Trefilova
ZNZaitun Nurgaliev
Zaitun Nurgaliev
MNMaxim A. Novitsky
Maxim A. Novitsky
RNRegina F. Nasyrova
Regina F. Nasyrova
The intervertebral disk degeneration (IDD) and its associated conditions are an important problem in modern medicine. The onset of IDD may be in childhood and adolescence in patients with a genetic predisposition. IDD progresses with age, leading to spondylosis, spondylarthrosis, intervertebral disk herniation, and spinal stenosis. The purpose of this review is an attempt to summarize the data characterizing the patterns of production of pro-inflammatory and anti-inflammatory cytokines in IDD and to appreciate the prognostic value of cytokine imbalance as its biomarker. This narrative review demonstrates that the problem of evaluating the contribution of pro-inflammatory and anti-inflammatory cytokines to the maintenance or alteration of cytokine balance may be a new key to unlocking the mystery of IDD development and new therapeutic strategies for the treatment of IDD in the setting of acute and chronic inflammation. The presented data support the hypothesis that cytokine imbalance is one of the most important biomarkers of IDD.

26 August 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
VTVera Trefilova
Vera Trefilova
Natalia A. ShnayderNatalia A. Shnayder
Natalia A. Shnayder
MPMarina Petrova
Marina Petrova
DKDaria S. Kaskaeva
Daria S. Kaskaeva
OTOlga V. Tutynina
Olga V. Tutynina
RNRegina F. Nasyrova
Regina F. Nasyrova
(1) Background: The purpose of this review is to analyze domestic and foreign studies on the role of collagen-encoding genes polymorphism in the development of intervertebral discs (IVDs) degeneration in humans. (2) Methods: We have carried out a search for full-text articles published in e-Library, PubMed, Oxford Press, Clinical Case, Springer, Elsevier and Google Scholar databases. The search was carried out using keywords and their combinations. The search depth was 5 years (2016–2021). In addition, this review includes articles of historical interest. Despite an extensive search, it is possible that we might have missed some studies published in recent years. (3) Results: According to the data of genome-wide and associative genetic studies, the following candidate genes that play a role in the biology of IVDs and the genetic basis of the processes of collagen degeneration of the annulus fibrosus and nucleus pulposus of IVDs in humans are of the greatest interest to researchers: COL1A1, COL2A1, COL9A2, COL9A3, COL11A1 and COL11A2. In addition, the role of genes COL1A2, COL9A1 and others is being actively studied. (4) Conclusions: In our review, we summarized and systematized the available information on the role of genetic factors in IVD collagen fibers turnover and also focused on the functions of different types of collagen present in the IVD. Understanding the etiology of impaired collagen formation can allow doctors to prescribe pathogenetically-based treatment, achieving the most effective results.

22 April 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
Natalia A. ShnayderNatalia A. Shnayder
Natalia A. Shnayder
MPMarina Petrova
Marina Petrova
PSPavel A. Shesternya
Pavel A. Shesternya
ASAlina Savinova
Alina Savinova
EBElena N. Bochanova
Elena N. Bochanova
RNRegina F. Nasyrova
Regina F. Nasyrova
Dabigatran, rivaroxaban, apixaban, and edoxaban are direct oral anticoagulants (DOACs) that are increasingly used worldwide. Taking into account their widespread use for the prevention of thromboembolism in cardiology, neurology, orthopedics, and coronavirus disease 2019 (COVID 19) as well as their different pharmacokinetics and pharmacogenetics dependence, it is critical to explore new opportunities for DOACs administration and predict their dosage when used as monotherapy or in combination with other drugs. In this review, we describe the details of the relative pharmacogenetics on the pharmacokinetics of DOACs as well as new data concerning the clinical characteristics that predetermine the needed dosage and the risk of adverse drug reactions (ADRs). The usefulness of genetic information before and shortly after the initiation of DOACs is also discussed. The reasons for particular attention to these issues are not only new genetic knowledge and genotyping possibilities, but also the risk of serious ADRs (primarily, gastrointestinal bleeding). Taking into account the effect of the carriership of single nucleotide variants (SNVs) of genes encoding biotransformation enzymes and DOACs metabolism, the use of these measures is important to predict changes in pharmacokinetics and the risk of ADRs in patients with a high risk of thromboembolism who receive anticoagulant therapy.

Verified
Journal Article
Open access
PDF file
Natalia A. ShnayderNatalia A. Shnayder
Natalia A. Shnayder
Aiperi Kylychbekovna KhasanovaAiperi Kylychbekovna Khasanova
Aiperi Kylychbekovna Khasanova
ASAnna Igorevna Strelnik
Anna Igorevna Strelnik
Mustafa Al-ZamilMustafa Al-Zamil
Mustafa Al-Zamil
AOAndrey P. Otmakhov
Andrey P. Otmakhov
RNRegina F. Nasyrova
Regina F. Nasyrova
Treatment-resistant schizophrenia (TRS) is an important and unresolved problem in biological and clinical psychiatry. Approximately 30% of cases of schizophrenia (Sch) are TRS, which may be due to the fact that some patients with TRS may suffer from pathogenetically “non-dopamine” Sch, in the development of which neuroinflammation is supposed to play an important role. The purpose of this narrative review is an attempt to summarize the data characterizing the patterns of production of pro-inflammatory and anti-inflammatory cytokines during the development of therapeutic resistance to APs and their pathogenetic and prognostic significance of cytokine imbalance as TRS biomarkers. This narrative review demonstrates that the problem of evaluating the contribution of pro-inflammatory and anti-inflammatory cytokines to maintaining or changing the cytokine balance can become a new key in unlocking the mystery of “non-dopamine” Sch and developing new therapeutic strategies for the treatment of TRS and psychosis in the setting of acute and chronic neuroinflammation. In addition, the inconsistency of the results of previous studies on the role of pro-inflammatory and anti-inflammatory cytokines indicates that the TRS biomarker, most likely, is not the serum level of one or more cytokines, but the cytokine balance. We have confirmed the hypothesis that cytokine imbalance is one of the most important TRS biomarkers. This hypothesis is partially supported by the variable response to immunomodulators in patients with TRS, which were prescribed without taking into account the cytokine balance of the relation between serum levels of the most important pro-inflammatory and anti-inflammatory cytokines for TRS.